肝硬化患者使用钙通道阻滞剂与静脉曲张出血风险
这项香港 territory-wide 回顾性队列研究纳入2000至2023年无静脉曲张出血史的肝硬化患者,采用活性对照新用户设计,比较钙通道阻滞剂(CCB)与ACE抑制剂/ARB单药治疗高血压的静脉曲张出血风险。
要点
- 肝硬化高血压患者使用CCB与ACE抑制剂/ARB相比,静脉曲张出血风险无显著差异。
- CCB组5年累积静脉曲张出血发生率为3.74%(95%CI 2.59%-4.87%)。
- 研究提示CCB可作为肝硬化合并高血压患者的安全降压选择。
核心结论
- 与ACE抑制剂/ARB相比,CCB使用与肝硬化患者静脉曲张出血风险增加无关。
- CCB可能是肝硬化合并高血压患者的安全治疗选择。
研究设计与样本
- 研究为香港医院管理局临床数据分析与报告系统2000至2023年的全港回顾性队列研究。
- 纳入无静脉曲张出血史的肝硬化患者,采用活性对照新用户设计,以ACE抑制剂/ARB为活性对照。
- CCB或ACE抑制剂/ARB作为高血压单药起始治疗,随访至停药、加药或换药时删失。
- 共纳入1886例CCB使用者和827例ACE抑制剂/ARB使用者,采用逆概率治疗加权分析。
主要发现
- CCB组5年累积静脉曲张出血发生率为3.74%(95%CI 2.59%-4.87%),ACE抑制剂/ARB组为4.17%(95%CI 2.25%-6.05%)。
临床怎么用
- 肝硬化合并高血压患者选用CCB降压时,无需因静脉曲张出血风险顾虑而避免使用。
- 临床决策时可结合患者具体情况,在CCB与ACE抑制剂/ARB之间个体化选择。
局限性
- 本研究为回顾性队列研究,可能存在未测量混杂因素。
- 研究基于香港全港数据库,结果外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Calcium-channel blockers (CCBs) are widely prescribed for arterial hypertension. However, it remains uncertain whether CCBs, through their vasodilatory effects, influence the risk of variceal hemorrhage (VH) in cirrhosis patients. This study aimed to investigate the association between CCB use and VH risk in cirrhosis patients. METHODS: This territory-wide retrospective cohort study included patients with cirrhosis and no prior history of VH identified from the Clinical Data Analysis and Reporting System of the Hospital Authority, Hong Kong between 2000 and 2023. An active comparator new-user design was adopted, with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) as active comparators. Either CCB or ACE inhibitor/ARB were initiated as monotherapy for hypertension. Patients were censored at discontinuation, addition, or switching of the medication. RESULTS: A total of 1886 CCB and 827 ACE inhibitor/ARB users were included. After inverse probability of treatment weighting, VH incidence rates were comparable between CCB and ACE inhibitor/ARB users (7.42 vs 10.50 cases per 1000 person-years; P = .116). The 5-year cumulative incidence was 3.74% (95% confidence interval [CI], 2.59%-4.87%) and 4.17% (95% CI, 2.25%-6.05%) for CCB and ACE inhibitor/ARB users, respectively. No significant association between CCB use and VH risk was observed (adjusted subdistribution hazard ratio 0.967; 95% CI, 0.616-1.518; P = .880). CONCLUSIONS: CCBs were not associated with an increased risk of VH in patients with cirrhosis compared with ACE inhibitors/ARBs. These findings suggest that CCBs are a safe treatment option for patients with cirrhosis and hypertension, providing valuable guidance on medication selection in this vulnerable population.
引用
- Dai J, Yip TC, Tse YK, et al. Risk of Variceal Hemorrhage in Patients With Cirrhosis Taking Calcium-Channel Blockers. Clin Gastroenterol Hepatol. 2025. PMID: 41270880. doi:10.1016/j.cgh.2025.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。